Syn-Coll vs PT-141 (Bremelanotide)
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Syn-CollSexual Health & Libido
PT-141 (Bremelanotide)- Summary
- Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
- PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
- Half-Life
- Extended (lipid depot in stratum corneum)
- 2–3 hours
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.005-0.05% in formulation
- 0.5–1.75 mg
- Frequency
- Once or twice daily
- As needed (not daily)
- Key Benefits
- Directly activates TGF-beta for potent collagen synthesis stimulation
- Increases dermal thickness and firmness
- Reduces depth of wrinkles and fine lines
- Improves skin elasticity
- Clinically validated in collagen induction studies
- Complementary to retinoids or vitamin C
- Enhances sexual desire and libido in both men and women
- Improves arousal through central nervous system activation
- Effective for psychological erectile dysfunction
- Works for female sexual arousal disorder
- May improve sexual satisfaction and intensity
- Fast-acting — effects within 45–60 minutes
- FDA-approved for HSDD in premenopausal women
- Side Effects
- Generally well-tolerated
- Rare mild irritation at high concentrations
- Possible sensitivity in individuals with inflammatory skin conditions
- Nausea (most common — 40% of users in clinical trials)
- Facial flushing and warmth
- Transient blood pressure changes (typically increase then normalize)
- Headache
- +2 more
- Stacks With
- —
- —